Prescription drugs cost less in other countries primarily because their governments negotiate prices directly with manufacturers, something the United States has historically not done. The gap is enormous: in 2022, Americans paid nearly three times as much as people in 33 other wealthy nations for the same medications. For brand-name drugs specifically, U.S. prices were 422% of what other countries paid. That means a brand-name drug costing $100 elsewhere carried a price tag of roughly $422 in the U.S.
Government Price Negotiation Is the Biggest Factor
In the United States, brand-name drug manufacturers have historically been free to set whatever price they want at launch. Most other industrialized countries take the opposite approach: prices are systematically negotiated based on how much clinical benefit a drug actually provides.
The UK offers a clear example of how this works. The National Institute for Health and Care Excellence (NICE) evaluates every new drug’s cost-effectiveness before the National Health Service will cover it. If a drug costs more than roughly £25,000 to £35,000 per year of healthy life it adds, NICE pushes back. Manufacturers must lower their list price or offer discounts until the drug falls within that range. The UK government can also cap a drug’s maximum price by factoring in development costs and profit margins. If a company refuses to budge, the drug simply doesn’t get covered for millions of patients, which gives the government real leverage.
Canada uses a different tool to similar effect. Its Patented Medicine Prices Review Board sets price ceilings for patented medications by comparing what 11 other industrialized countries pay, then capping Canadian prices accordingly. Germany does something similar for innovative drugs that lack direct competitors, referencing prices from 15 European countries as a baseline for negotiations. In every case, there is a government body with the authority to say “no” to a price it considers unreasonable. That single word, backed by a large block of patients, is what keeps prices lower.
The U.S. System Inflates List Prices
Rather than direct government negotiation, the U.S. has relied on private intermediaries called pharmacy benefit managers (PBMs) to negotiate drug costs on behalf of insurers and employers. PBMs process claims, manage drug formularies, and negotiate rebates with manufacturers. Those rebates are essentially delayed discounts: a manufacturer agrees to return a percentage of the drug’s price after the sale.
The problem is that this system creates a perverse incentive. Manufacturers can set high list prices knowing that rebates will bring the net cost down for insurers. But not everyone benefits from those rebates. Patients without insurance, or those with high-deductible plans, often pay based on the inflated list price rather than the lower negotiated price. Even after accounting for all rebates paid to U.S. payers and PBMs, brand-name drug prices in the U.S. were still 308% of prices in other countries in 2022. The rebate system narrows the gap but doesn’t come close to eliminating it.
Insulin Shows How Extreme the Gap Can Get
Insulin is one of the most striking examples. In 2018, the average manufacturer price for a standard unit of insulin in the U.S. was $98.70. Across 32 other wealthy nations, that same standard unit averaged $8.81. That’s more than a tenfold difference for a medication discovered over a century ago that millions of people need to survive.
The insulin case illustrates how all the structural differences compound. Other countries negotiated prices down. The U.S. didn’t. Multiple manufacturers set similar high prices. PBM rebates reduced costs for some payers but left many patients exposed to the full list price. The result was a drug that cost pennies to produce being sold for prices that forced some Americans to ration their doses.
Generic Drugs Are Actually Cheaper in the U.S.
Here’s a detail that surprises most people: the U.S. is not more expensive across the board. Unbranded generic drugs in the U.S. cost about 67% of what other countries pay, making them roughly a third cheaper. The U.S. also uses generics far more aggressively. Generics account for 90% of all prescriptions filled in the U.S., compared to about 41% in other wealthy nations.
This means the U.S. drug market is essentially split in two. The generic side is competitive, high-volume, and relatively affordable. The brand-name side is where prices spiral. Because brand-name drugs carry such dramatically higher price tags (more than four times international averages), they dominate total spending even though they represent only about 10% of prescriptions. That imbalance is why overall U.S. drug spending still lands at 278% of the international average.
Patent Rules Keep Brand-Name Drugs on the Market Longer
Both the U.S. and Europe allow drug companies to extend their patents to compensate for time lost during the regulatory approval process. In Europe, Supplementary Protection Certificates can extend patent protection by up to five and a half years. The U.S. has similar provisions tied to the approved active ingredient.
Where the systems diverge is in how easily generic competitors can enter the market. In Europe, generic companies can challenge a patent through a centralized post-grant opposition process at the European Patent Office, and they have nine months to do so. This creates a faster pathway for generics to reach the market. In the U.S., the Hatch-Waxman Act allows generic manufacturers to file abbreviated applications, but the legal process for challenging patents can be slower and more costly. Courts in both regions have placed limits on “evergreening,” where companies try to extend monopoly protection through minor modifications like new dosage forms or combinations. But delays of even a year or two in generic entry can mean billions in additional brand-name revenue in the U.S., where there’s no price ceiling to begin with.
The U.S. Is Starting to Change
For the first time, the U.S. government has begun negotiating drug prices directly. Under the Inflation Reduction Act, Medicare selected its first 10 drugs for price negotiation, with new prices taking effect in 2026. The list includes widely used medications for diabetes (Jardiance, Januvia, Farxiga, Fiasp/NovoLog), blood clots (Eliquis, Xarelto), heart failure (Entresto), psoriasis and rheumatoid arthritis (Stelara, Enbrel), and blood cancer (Imbruvica).
The estimated impact is meaningful but modest. If the negotiated prices had been in effect in 2023, Medicare would have saved roughly $6 billion on those 10 drugs alone, a net savings of 22%. That’s real money, but it covers only a small fraction of the thousands of drugs on the market. The program is expected to expand to more drugs in coming years, gradually moving the U.S. closer to the negotiation models that other countries have used for decades.
Can You Buy Drugs From Other Countries?
Given the price differences, many Americans wonder whether they can simply purchase medications abroad. Legally, importing drugs into the U.S. for personal use is generally prohibited. Products purchased from foreign pharmacies typically haven’t gone through FDA approval, and the agency cannot verify their safety or effectiveness.
That said, FDA enforcement allows some flexibility. If you’re importing a prescription drug for a serious condition with no effective domestic treatment available, the product doesn’t pose an unreasonable risk, and you’re bringing in no more than a three-month supply for personal use, FDA personnel may allow it. You’d need to provide the name of a U.S.-licensed doctor responsible for your care or show that you’re continuing treatment started in another country. This isn’t a formal exemption or a right. It’s an exercise of enforcement discretion, and it can vary case by case. Controlled substances face additional scrutiny from the Drug Enforcement Administration.